JP2014525459A - Ｈ−ホスホネート−エン／ｈ−ホスホネート−インヒドロホスホニル化反応を用いた標的化ナノ粒子のリモートアセンブリ - Google Patents

Ｈ−ホスホネート−エン／ｈ−ホスホネート−インヒドロホスホニル化反応を用いた標的化ナノ粒子のリモートアセンブリ Download PDF

Info

Publication number
JP2014525459A
JP2014525459A JP2014528613A JP2014528613A JP2014525459A JP 2014525459 A JP2014525459 A JP 2014525459A JP 2014528613 A JP2014528613 A JP 2014528613A JP 2014528613 A JP2014528613 A JP 2014528613A JP 2014525459 A JP2014525459 A JP 2014525459A
Authority
JP
Japan
Prior art keywords
group
agent
agents
compound
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014528613A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014525459A5 (enExample
Inventor
トーマス イー． ロジャーズ，
カー チオン クアン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Publication of JP2014525459A publication Critical patent/JP2014525459A/ja
Publication of JP2014525459A5 publication Critical patent/JP2014525459A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014528613A 2011-08-31 2012-08-30 Ｈ−ホスホネート−エン／ｈ−ホスホネート−インヒドロホスホニル化反応を用いた標的化ナノ粒子のリモートアセンブリ Pending JP2014525459A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161529665P 2011-08-31 2011-08-31
US61/529,665 2011-08-31
PCT/US2012/053211 WO2013033450A2 (en) 2011-08-31 2012-08-30 Remote assembly of targeted nanoparticles using h-phosphonate-ene/-yne hydrophosphonylation reactions

Publications (2)

Publication Number Publication Date
JP2014525459A true JP2014525459A (ja) 2014-09-29
JP2014525459A5 JP2014525459A5 (enExample) 2015-10-15

Family

ID=46832627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014528613A Pending JP2014525459A (ja) 2011-08-31 2012-08-30 Ｈ−ホスホネート−エン／ｈ−ホスホネート−インヒドロホスホニル化反応を用いた標的化ナノ粒子のリモートアセンブリ

Country Status (9)

Country Link
US (2) US9216225B2 (enExample)
EP (1) EP2750711A2 (enExample)
JP (1) JP2014525459A (enExample)
KR (1) KR20140064917A (enExample)
CN (1) CN103945869A (enExample)
BR (1) BR112014004716A2 (enExample)
CA (1) CA2845851A1 (enExample)
IL (1) IL231216A0 (enExample)
WO (1) WO2013033450A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019009434A1 (ja) * 2017-07-06 2019-01-10 学校法人京都薬科大学 薬物送達用高分子ミセル

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9918190B2 (en) * 2015-02-18 2018-03-13 Cisco Technology, Inc. Augmenting network device management
FR3046728B1 (fr) * 2016-01-19 2020-04-03 Centre National De La Recherche Scientifique Nouvelles nanoparticules d'organosilice mesoporeuses, leur methode de preparation et leurs utilisations.

Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940961A (en) * 1957-08-09 1960-06-14 Eastman Kodak Co Alkyl 1-acetoxyalkenylphosphonates and polymers thereof
US3006945A (en) * 1960-09-01 1961-10-31 Ethyl Corp Preparation of organic compounds
US3224973A (en) * 1960-09-01 1965-12-21 Ethyl Corp Dialkyl hydroxybenzyl phosphonates as antioxidants
US3367870A (en) * 1963-09-12 1968-02-06 Geigy Chem Corp Method of stabilization with carbonbonded phosphorus derivatives and compositions stabilized thereby
JPS5677291A (en) * 1979-07-09 1981-06-25 Elf Aquitaine Phosphoric acid ester* its manufacture and its use
JPS62167790A (ja) * 1985-11-04 1987-07-24 ザ、プロクタ−、エンド、ギヤンブル、カンパニ− エテニリデンビスホスホン酸テトラアルキルの合成法
JPS63166895A (ja) * 1986-12-20 1988-07-11 ヘキスト・アクチエンゲゼルシヤフト ハロゲン化ホスホノ燐酸エステルの製造法
US4798872A (en) * 1986-04-28 1989-01-17 Ashland Oil, Inc. Alkylene phosphonate acid ester polyols
JPH01165585A (ja) * 1987-11-24 1989-06-29 F Hoffmann La Roche Ag 薬理学的に活性なカルボン酸のエステル類
US5321153A (en) * 1992-06-15 1994-06-14 Monsanto Company Process for making chiral alpha-amino phosphonates selected novel chiral alpha-amino phosphonates
JPH07140615A (ja) * 1993-11-12 1995-06-02 Fuji Photo Film Co Ltd ハロゲン化銀カラー感光材料
JPH07140606A (ja) * 1993-11-19 1995-06-02 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
WO1996024599A1 (en) * 1995-02-10 1996-08-15 Akzo Nobel N.V. Synthesis of a hydrocarbylvinyl phosphonic acid hydrocarbyl ester
JPH09136895A (ja) * 1995-09-14 1997-05-27 Agency Of Ind Science & Technol 不飽和ホスホン酸エステルの製造方法
JPH09510721A (ja) * 1994-03-26 1997-10-28 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な２，４−ジホスホノグルタール酸誘導体、その製造方法及び該化合物を含有する医薬
JP2000256380A (ja) * 1999-03-08 2000-09-19 Agency Of Ind Science & Technol 不飽和ホスホン酸エステルの製造方法
JP2000513372A (ja) * 1996-06-28 2000-10-10 ザ ユニバーシティー オブ リバプール ステロイドビスホスホネート
JP2001253890A (ja) * 2000-03-13 2001-09-18 Natl Inst Of Advanced Industrial Science & Technology Meti （α−及び／又はβ−ホルミルエチル）ホスフィンオキシド化合物、（α−及び／又はβ−ホルミルエチル）ホスホン酸エステル化合物とその製造方法
WO2003094851A2 (en) * 2002-05-11 2003-11-20 Ilex Products, Inc. 1,1- and 1,2-bisphosphonates as apoliprotein e modulators
JP2004500352A (ja) * 1999-12-03 2004-01-08 ザ　レジェンツ　オブ　ザ　ユニバーシティー　オブ　カリフォルニア　サン　ディエゴ ホスホネート化合物
JP2004026655A (ja) * 2002-05-17 2004-01-29 Japan Science & Technology Corp アルケニルリン化合物の製造方法
JP2004522703A (ja) * 2000-10-23 2004-07-29 アイレックス プロダクツ， インコーポレイテッド β置換されるβアミノエチルホスホネート
JP2005232067A (ja) * 2004-02-18 2005-09-02 National Institute Of Advanced Industrial & Technology 含リンブタジエン化合物の製造方法
CN1887890A (zh) * 2006-07-17 2007-01-03 华中师范大学 具有除草活性的α－酰氧基烯基膦酸酯及制备
CN1903862A (zh) * 2006-07-20 2007-01-31 华中师范大学 具有除草活性的取代甲酰氧基烃基膦酸酯类光学活性异构体及制备
JP2007518746A (ja) * 2004-01-23 2007-07-12 エムツェーエス マイクロ キャリアー システムズ ゲーエムベーハー 脂質由来ビスホスホン酸
WO2009145263A1 (ja) * 2008-05-30 2009-12-03 学校法人東京理科大学 リン酸オセルタミビルの製造方法及び中間体化合物
JP2010500050A (ja) * 2006-04-27 2010-01-07 シェノイ，ナルマダ，アール． 身体通路の疾病を治療又は予防する組成物及び方法
JP2010540605A (ja) * 2007-10-05 2010-12-24 ゲルベ 親水性生体内分布リガンドにカップリングされたｇｅｍ−ビスホスホネート安定化層で覆われるナノ粒子を調製する新規な方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681481A (en) 1969-11-12 1972-08-01 Hooker Chemical Corp Catalytic addition of compounds having a p-h bond to acetylene
EP0023173B1 (fr) * 1979-07-09 1983-12-14 Societe Nationale Elf Aquitaine (Production) Nouveaux esters diphosphoniques et triphosphoniques, leurs préparation et applications
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
DE10049074A1 (de) 2000-10-02 2002-04-18 Andreas Kage Verfahren zur Selektion hochaffin an ein Target bindender Nukleinsäuren
DE10054218A1 (de) 2000-11-02 2002-05-08 Basf Ag Verfahren zur Herstellung von Alkenylphosphonsäure-Derivaten
WO2006078646A2 (en) 2005-01-18 2006-07-27 Caltagirone Gaetano T A class of supramolecular drug molecules and methods of identification and use thereof
EP2533764A4 (en) * 2010-02-08 2016-08-31 Univ Nebraska BIOMINERAL AND METAL BINDING LIPOSOME, THEIR SYNTHESIS AND METHOD FOR THE PRODUCTION THEREOF

Patent Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940961A (en) * 1957-08-09 1960-06-14 Eastman Kodak Co Alkyl 1-acetoxyalkenylphosphonates and polymers thereof
US3006945A (en) * 1960-09-01 1961-10-31 Ethyl Corp Preparation of organic compounds
US3224973A (en) * 1960-09-01 1965-12-21 Ethyl Corp Dialkyl hydroxybenzyl phosphonates as antioxidants
US3367870A (en) * 1963-09-12 1968-02-06 Geigy Chem Corp Method of stabilization with carbonbonded phosphorus derivatives and compositions stabilized thereby
JPS5677291A (en) * 1979-07-09 1981-06-25 Elf Aquitaine Phosphoric acid ester* its manufacture and its use
JPS62167790A (ja) * 1985-11-04 1987-07-24 ザ、プロクタ−、エンド、ギヤンブル、カンパニ− エテニリデンビスホスホン酸テトラアルキルの合成法
US4798872A (en) * 1986-04-28 1989-01-17 Ashland Oil, Inc. Alkylene phosphonate acid ester polyols
JPS63166895A (ja) * 1986-12-20 1988-07-11 ヘキスト・アクチエンゲゼルシヤフト ハロゲン化ホスホノ燐酸エステルの製造法
JPH01165585A (ja) * 1987-11-24 1989-06-29 F Hoffmann La Roche Ag 薬理学的に活性なカルボン酸のエステル類
US5321153A (en) * 1992-06-15 1994-06-14 Monsanto Company Process for making chiral alpha-amino phosphonates selected novel chiral alpha-amino phosphonates
JPH07140615A (ja) * 1993-11-12 1995-06-02 Fuji Photo Film Co Ltd ハロゲン化銀カラー感光材料
JPH07140606A (ja) * 1993-11-19 1995-06-02 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
JPH09510721A (ja) * 1994-03-26 1997-10-28 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な２，４−ジホスホノグルタール酸誘導体、その製造方法及び該化合物を含有する医薬
WO1996024599A1 (en) * 1995-02-10 1996-08-15 Akzo Nobel N.V. Synthesis of a hydrocarbylvinyl phosphonic acid hydrocarbyl ester
JPH09136895A (ja) * 1995-09-14 1997-05-27 Agency Of Ind Science & Technol 不飽和ホスホン酸エステルの製造方法
JP2000513372A (ja) * 1996-06-28 2000-10-10 ザ ユニバーシティー オブ リバプール ステロイドビスホスホネート
JP2000256380A (ja) * 1999-03-08 2000-09-19 Agency Of Ind Science & Technol 不飽和ホスホン酸エステルの製造方法
JP2004500352A (ja) * 1999-12-03 2004-01-08 ザ　レジェンツ　オブ　ザ　ユニバーシティー　オブ　カリフォルニア　サン　ディエゴ ホスホネート化合物
JP2001253890A (ja) * 2000-03-13 2001-09-18 Natl Inst Of Advanced Industrial Science & Technology Meti （α−及び／又はβ−ホルミルエチル）ホスフィンオキシド化合物、（α−及び／又はβ−ホルミルエチル）ホスホン酸エステル化合物とその製造方法
JP2004522703A (ja) * 2000-10-23 2004-07-29 アイレックス プロダクツ， インコーポレイテッド β置換されるβアミノエチルホスホネート
WO2003094851A2 (en) * 2002-05-11 2003-11-20 Ilex Products, Inc. 1,1- and 1,2-bisphosphonates as apoliprotein e modulators
JP2004026655A (ja) * 2002-05-17 2004-01-29 Japan Science & Technology Corp アルケニルリン化合物の製造方法
JP2007518746A (ja) * 2004-01-23 2007-07-12 エムツェーエス マイクロ キャリアー システムズ ゲーエムベーハー 脂質由来ビスホスホン酸
JP2005232067A (ja) * 2004-02-18 2005-09-02 National Institute Of Advanced Industrial & Technology 含リンブタジエン化合物の製造方法
JP2010500050A (ja) * 2006-04-27 2010-01-07 シェノイ，ナルマダ，アール． 身体通路の疾病を治療又は予防する組成物及び方法
CN1887890A (zh) * 2006-07-17 2007-01-03 华中师范大学 具有除草活性的α－酰氧基烯基膦酸酯及制备
CN1903862A (zh) * 2006-07-20 2007-01-31 华中师范大学 具有除草活性的取代甲酰氧基烃基膦酸酯类光学活性异构体及制备
JP2010540605A (ja) * 2007-10-05 2010-12-24 ゲルベ 親水性生体内分布リガンドにカップリングされたｇｅｍ−ビスホスホネート安定化層で覆われるナノ粒子を調製する新規な方法
WO2009145263A1 (ja) * 2008-05-30 2009-12-03 学校法人東京理科大学 リン酸オセルタミビルの製造方法及び中間体化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6016013847; Ｓｙｎｌｅｔｔ Ｖｏｌ．１５, 2009, ｐ．２３７５-２３８１ *
JPN6016013848; Ｈｅｔｅｒｏａｔｏｍ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．１１（７）, 2000, ｐ．５１８-５２７ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019009434A1 (ja) * 2017-07-06 2019-01-10 学校法人京都薬科大学 薬物送達用高分子ミセル

Also Published As

Publication number Publication date
CN103945869A (zh) 2014-07-23
EP2750711A2 (en) 2014-07-09
IL231216A0 (en) 2014-04-30
WO2013033450A2 (en) 2013-03-07
KR20140064917A (ko) 2014-05-28
US20130066098A1 (en) 2013-03-14
WO2013033450A3 (en) 2013-09-06
CA2845851A1 (en) 2013-03-07
US9216225B2 (en) 2015-12-22
BR112014004716A2 (pt) 2017-03-28
US20160060280A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
JP5927194B2 (ja) 治療ナノキャリアおよび／または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート
US8889657B2 (en) Nanoparticle PEG modification with H-phosphonates
JP6549172B2 (ja) がん治療用組合せリポソーム組成物
JP6294456B2 (ja) 修飾されたドセタキセルリポソーム製剤
US8871189B2 (en) MMP-targeted therapeutic and/or diagnostic nanocarriers
JP2014528411A (ja) 相補的オリゴヌクレオチドリンカーを用いる標的化ナノ粒子の遠隔アセンブリ
US20160060280A1 (en) Remote Assembly of Targeted Nanoparticles Using H-Phosphonate -ENE/-YNE Hydrophosphonylation Reactions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150828

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160412

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161107